Avalyn Pharma Inc. Common Stock (AVLN) vs GoodRx Holdings, Inc. (GDRX)
A side-by-side comparison of Avalyn Pharma Inc. Common Stock and GoodRx Holdings, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
AVLN
Avalyn Pharma Inc. Common Stock
$25.52HealthcareDelayed quote: Oct 6, 2026, 10:45 AM EDT
GDRX
GoodRx Holdings, Inc.
$3.34HealthcareDelayed quote: Oct 6, 2026, 10:45 AM EDT
Total return — AVLN vs GDRX
growth of $100 · dividends reinvested · last 1yAVLN -8.3% (-8.3%/yr)GDRX +42.4% (+42.4%/yr)GDRX compounded faster over this window
AVLN GDRX
AVLN vs GDRX: by the numbers
- •GDRX is the larger company ($1.16B vs $1.13B market cap).
- •GDRX is profitable (2.07% net margin) while AVLN runs a net loss (0.00%).
Metrics side by side
Valuation
| Metric | AVLN | GDRX |
|---|---|---|
| P/E ratio | N/A | 78.47 |
| P/S ratio | N/A | 1.47 |
| P/B ratio | 2.84 | 1.79 |
| EV / EBITDA | N/A | 8.27 |
| FCF yield | N/A | 12.61% |
Profitability
| Metric | AVLN | GDRX |
|---|---|---|
| Gross margin | 0.00% | 88.05% |
| Operating margin | 0.00% | 10.25% |
| Net margin | 0.00% | 2.07% |
| ROE | N/A | 2.51% |
| ROIC | -67.73% | 3.72% |
Growth (annualized)
| Metric | AVLN | GDRX |
|---|---|---|
| Revenue CAGR (5Y) | N/A | 4.47% |
| FCF CAGR (5Y) | N/A | 11.72% |
| Total return CAGR (5Y) | N/A | -39.98% |
Frequently asked
- Is AVLN or GDRX more profitable?
- GDRX runs the higher net margin — AVLN at 0.00% versus GDRX at 2.07%.
Go deeper
Dig into the metrics
GoodRx P/E ratioAvalyn Pharma Inc. Common Stock ROEGoodRx ROEAvalyn Pharma Inc. Common Stock operating marginGoodRx operating marginAvalyn Pharma Inc. Common Stock revenue growthGoodRx revenue growthAvalyn Pharma Inc. Common Stock free cash flowGoodRx free cash flow
Avalyn Pharma Inc. Common Stock & GoodRx appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.